InsiderTrades

Form 4 for ALKS Alkermes plc.

Accepted 2024-02-13 00:00:00 ET · period of report 2024-02-10 · accession 0001127602-24-004741 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2024-02-13 2024-02-10 ALKS MCKEON BRIAN P Dir F - Tax $27.32 -1,088 23.1K -4% -$29.7K
D 2024-02-13 2024-02-10 ALKS MCKEON BRIAN P Dir M - OptEx — +4,533 24.2K +23% —
DM 2024-02-13 2023-11-17 ALKS MCKEON BRIAN P Dir J - Other $25.73 +1,618 13.0K +14% +$41.6K
D 2024-02-13 2024-02-10 ALKS MCKEON BRIAN P Dir M - OptEx — -4,533 0 -100% —

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Ordinary Shares 2024-02-10 F D 1,088 $27.32 23,141 D — —
2 Common Ordinary Shares 2024-02-10 M A 4,533 — 24,229 D — — (F1) Each restricted stock unit represents a contingent right to receive one ordinary share.
3 Derivative Restricted Stock Unit Award 2023-11-17 J A 119 — 6,104 D — · 2024-06-29 to — 119 Ordinary Shares (F3) Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5. (F1) Each restricted stock unit represents a contingent right to receive one ordinary share. (F7) Shares subject to the restricted stock unit award vest in full on 6/29/2024.
4 Derivative Restricted Stock Unit Award 2024-02-10 M D 4,533 — 0 D — · — to — 4,533 Ordinary Shares (F1) Each restricted stock unit represents a contingent right to receive one ordinary share. (F5) This award is fully vested in accordance with its terms.
5 Derivative Non Qualified Stock Option (Right to Buy) 2023-11-17 J A 231 $30.86 11,785 D $30.86 · — to 2032-07-07 231 Ordinary Shares (F3) Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5. (F4) These options are fully vested in accordance with their terms.
6 Derivative Non Qualified Stock Option (Right to Buy) 2023-11-17 J A 313 $24.24 15,990 D $24.24 · — to 2031-06-14 313 Ordinary Shares (F3) Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5. (F4) These options are fully vested in accordance with their terms.
7 Derivative Restricted Stock Unit Award 2023-11-17 J A 88 — 4,533 D — · — to — 88 Ordinary Shares (F3) Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5. (F1) Each restricted stock unit represents a contingent right to receive one ordinary share. (F5) This award is fully vested in accordance with its terms.
8 Derivative Non Qualified Stock Option (Right to Buy) 2023-11-17 J A 523 $22.48 26,692 D $22.48 · — to 2031-02-10 523 Ordinary Shares (F3) Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5. (F4) These options are fully vested in accordance with their terms.
9 Derivative Non Qualified Stock Option (Right to Buy) 2023-11-17 J A 90 $22.48 4,639 D $22.48 · — to 2031-02-10 90 Ordinary Shares (F3) Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5. (F4) These options are fully vested in accordance with their terms.
10 Derivative Non Qualified Stock Option (Right to Buy) 2023-11-17 J A 254 $30.72 12,986 D $30.72 · 2024-06-29 to 2033-06-29 254 Ordinary Shares (F3) Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5. (F6) Shares subject to the stock option award vest and become exercisable in full on 6/29/2024.